Sitafit
Generic Name
Sitagliptin
Manufacturer
Healthcare Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| sitafit 50 mg tablet | ৳ 18.00 | ৳ 180.00 |
Description
Overview of the medicine
Sitafit 50 mg Tablet is an oral antidiabetic medicine used to treat type 2 diabetes mellitus. It helps to control blood sugar levels by increasing the release of insulin from the pancreas and decreasing the amount of sugar the liver makes.
Uses & Indications
Dosage
Adults
The usual recommended dose of sitagliptin is 100 mg once daily. For 50 mg tablets, dosage might be 50 mg once daily or two 50 mg tablets for 100 mg dose, based on doctor's advice.
Elderly
No dose adjustment needed based on age alone, but renal function should be assessed.
Renal_impairment
Mild renal impairment (eGFR ≥ 45 to < 90 mL/min): No dose adjustment. Moderate renal impairment (eGFR ≥ 30 to < 45 mL/min): 50 mg once daily. Severe renal impairment (eGFR < 30 mL/min) or ESRD requiring dialysis: 25 mg once daily.
How to Take
Administer orally once daily with or without food.
Mechanism of Action
Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). DPP-4 is an enzyme that degrades incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, Sitagliptin increases the levels of active incretin hormones, which in turn enhance glucose-dependent insulin secretion and suppress glucagon secretion from the pancreas. This leads to improved glycemic control.
Pharmacokinetics
Onset
Blood glucose lowering effect can be observed within a few hours.
Excretion
Primarily renal excretion (about 79% unchanged).
Half life
Approximately 12.4 hours.
Absorption
Rapidly absorbed after oral administration. Peak plasma concentrations reached within 1 to 4 hours. Absolute bioavailability is approximately 87%.
Metabolism
Primarily excreted unchanged in urine. Minor metabolism by CYP3A4 and CYP2C8.
Side Effects
Contraindications
- Known hypersensitivity to sitagliptin or any component of the tablet.
- Patients with type 1 diabetes mellitus or diabetic ketoacidosis.
Drug Interactions
Digoxin
Sitagliptin causes a slight increase in digoxin plasma levels. No dosage adjustment is generally required, but caution is advised.
Cyclosporine
Co-administration did not alter sitagliptin pharmacokinetics.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, employ usual supportive measures. Hemodialysis is modestly effective in removing sitagliptin.
Pregnancy & Lactation
Pregnancy Category B. Use only if clearly needed. It is not known whether sitagliptin is excreted in human milk; caution is advised when administered to a nursing woman.
Side Effects
Contraindications
- Known hypersensitivity to sitagliptin or any component of the tablet.
- Patients with type 1 diabetes mellitus or diabetic ketoacidosis.
Drug Interactions
Digoxin
Sitagliptin causes a slight increase in digoxin plasma levels. No dosage adjustment is generally required, but caution is advised.
Cyclosporine
Co-administration did not alter sitagliptin pharmacokinetics.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, employ usual supportive measures. Hemodialysis is modestly effective in removing sitagliptin.
Pregnancy & Lactation
Pregnancy Category B. Use only if clearly needed. It is not known whether sitagliptin is excreted in human milk; caution is advised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from manufacturing date
Availability
Available in pharmacies and hospitals
Approval Status
Approved by regulatory bodies (e.g., FDA, DGDA)
Patent Status
Generic versions available
Clinical Trials
Sitagliptin has undergone extensive clinical trials demonstrating its efficacy and safety in managing type 2 diabetes. Post-marketing surveillance continues to monitor its long-term effects.
Lab Monitoring
- Glycated hemoglobin (HbA1c) every 3-6 months.
- Renal function (eGFR) periodically.
Doctor Notes
- Regularly assess renal function, especially for dose adjustments.
- Educate patients on symptoms of pancreatitis and severe arthralgia.
- Monitor for signs of hypersensitivity reactions.
Patient Guidelines
- Take the medicine regularly as prescribed.
- Follow a healthy diet and exercise plan.
- Be aware of hypoglycemia symptoms if used with sulfonylurea or insulin.
- Report any unusual symptoms like severe abdominal pain or persistent joint pain.
Missed Dose Advice
If a dose is missed, it should be taken as soon as it is remembered. If it is close to the time for the next dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. Do not double the dose to make up for a missed one.
Driving Precautions
Sitafit is not expected to affect driving ability, but be aware of hypoglycemia symptoms if used with sulfonylurea or insulin.
Lifestyle Advice
- Maintain a balanced diet.
- Limit intake of sugary foods.
- Engage in regular moderate-intensity exercise.
- Monitor blood sugar levels regularly.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.